eXoZymes Reports Q4 and Full Year 2025 Results

Biotech firm touts AI-powered enzyme breakthroughs in nutraceuticals and pharmaceuticals.

Mar. 31, 2026 at 11:10pm

Got story updates? Submit your updates here. ›

eXoZymes Inc., a Los Angeles-based biotech company pioneering AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines, today provided an update on its Q4 and full-year 2025 operations. The company will host a conference call with investors later today to discuss the results.

Why it matters

eXoZymes is at the forefront of using artificial intelligence to develop new enzymes with applications across the nutraceutical and pharmaceutical industries. Its technology platform has the potential to unlock new sources of valuable compounds from renewable feedstocks, reducing reliance on limited natural resources.

The details

In its update, eXoZymes highlighted several key milestones from 2025, including the successful scale-up of its AI-powered enzyme production process, the launch of new nutraceutical products, and the advancement of multiple drug candidates into clinical trials. The company also reported strong financial results, with full-year revenue exceeding previous guidance.

  • eXoZymes will host a conference call today, March 31, 2026, at 5:30 PM Eastern Time to discuss the results.
  • The company provided an update on its Q4 and full-year 2025 operations.

The players

eXoZymes Inc.

A Los Angeles-based biotech company pioneering AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines.

Got photos? Submit your photos here. ›

What’s next

Investors can access the conference call details on the eXoZymes website, and a replay will be available shortly after the conclusion of the live event.

The takeaway

eXoZymes' innovative use of AI to develop novel enzymes with diverse applications positions the company as a leader in the rapidly evolving fields of nutraceuticals and pharmaceutical drug discovery.